PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLZOZIxNThizszN M2HiVFI1NzR6L{eyJIg> NV;ZV2d6cW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> NHTmXG4zPjJ{NE[4NS=>
SH-SY5Y NEPBRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXsNE05KM7:TR?= NXvxOXl1OjRxNEivO|IhcA>? NVftdmNicW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> M2nJd|I3OjJ2Nkix
SH-SY5Y  MXLBdI9xfG:|aYOgRZN{[Xl? NX\SRoRbOSEQvF2= MnfjNE42NTJ2IHi= MWjz[Y5{cXSrenXzJI5mfXKxYnzhd5RwdWFiY3XscJMhfG9iZH;4c5J2[mmlaX6tbY5lfWOnZDDhdI9xfG:|aYO= MnzyNlYzOjR4OEG=
G 35 SC NI\zW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnoNE4xPS1{MDFOwG0> NWjxbWtJOjRxN{KgbC=> NXf4WoRUTE2VTx?= NFfOe5FqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 M33DVVI3OTJzMkWx
G 38 SC M3:zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[xO2RLOC5yNT2yNEDPxE1? MV:yOE84OiCq MUDEUXNQ MULpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M3rXXVI3OTJzMkWx
G 40 SC NWLQOIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO4NE4xPS1{MDFOwG0> MVSyOE84OiCq M3LrVGROW09? MV7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M4L0TVI3OTJzMkWx
G 35 DC MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm2NE4xPS1{MDFOwG0> MmDUNlQwPzJiaB?= MkPKSG1UVw>? MWrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MWCyOlEzOTJ3MR?=
G 38 DC NFfWeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq5O2RuOC5yNT2yNEDPxE1? MYqyOE84OiCq MnvKSG1UVw>? NFjW[ZVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 M2m0SlI3OTJzMkWx
G 40 DC Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHjXHRIOC5yNT2yNEDPxE1? MnrWNlQwPzJiaB?= MmTnSG1UVw>? Mm\pbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MVWyOlEzOTJ3MR?=
RD NYHvUWl7SXCxcITvd4l{KEG|c3H5 Mlj1NU8yNjVxMjFOwG0> MYW3NkBp NGHGRpFqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? MUKyOVc1QTN5OB?=
TE381.T NFXFUZpCeG:ydH;zbZMhSXO|YYm= NWjTT41uOS9zLkWvNkDPxE1? MVO3NkBp MYHpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NVjLUZREOjV5NEmzO|g>
RMS13 NU\k[mNMSXCxcITvd4l{KEG|c3H5 M2XGS|EwOS53L{Kg{txO Mn\PO|IhcA>? NIPEV|FqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? NFvYUIEzPTd2OUO3PC=>
RH30  M{fiXGFxd3C2b4Ppd{BCe3OjeR?= NFTjd28yNzFwNT:yJO69VQ>? M{X1[lczKGh? NEnGdppqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? M1LDUVI2PzR7M{e4
VJ NXTYN28zSXCxcITvd4l{KEG|c3H5 M2LlblEwOS53L{Kg{txO NXvBPJNGPzJiaB?= MYDpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NHnQUVkzPTd2OUO3PC=>
HS578T MmPWR4VtdCCYaXHibYxqfHliQYPzZZk> NFLGUnMxNTNizszN M1TNSlczKGh? NEXZN3hqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NIjtNWkzPTd{MUSxPS=>
BT549 M1HLc2NmdGxiVnnhZoltcXS7IFHzd4F6 Mn\hNE0{KM7:TR?= M4TSV|czKGh? MmDjbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MWqyOVczOTRzOR?=
MDA-MB-231 NUK5doNyS2WubDDWbYFjcWyrdImgRZN{[Xl? M3j1V|AuOyEQvF2= MnK1O|IhcA>? NXLlVJl7cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MmXxNlU4OjF2MUm=
MDA-MB-468 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2\V[VAuOyEQvF2= NHnCZY84OiCq M1vURolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M1PKOFI2PzJzNEG5
MDA-MB-436 MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MorLNE0{KM7:TR?= MnnqO|IhcA>? MV\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MoLGNlU4OjF2MUm=
SUM149PT MnP1R4VtdCCYaXHibYxqfHliQYPzZZk> MnHPNE0{KM7:TR?= NYTG[o13PzJiaB?= NXzNUoNWcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NHHVTnAzPTd{MUSxPS=>
MDA-MB-468 NXju[Yx7TnWwY4Tpc44hSXO|YYm= MYGwMlAyNTFyIN88US=> MkHFNlQhcA>? M2\LN4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? NEXodJczPTd{MUSxPS=>
MDA-MB-231 NXXk[ldxTnWwY4Tpc44hSXO|YYm= NGHzWmsxNjBzLUGwJO69VQ>? NEjOTWQzPCCq MnfQ[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? MmnINlU4OjF2MUm=
HS578T Ml3LSpVv[3Srb36gRZN{[Xl? Mn[1NE4xOS1zMDFOwG0> MnLiNlQhcA>? NH\IWXhld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li NWDVUWVjOjV5MkG0NVk>
SW872 MYfGeY5kfGmxbjDBd5NigQ>? NVWwZ|h7OC5yMT2wMlUh|ryP MUWyOEBp NH\1[pZz\WS3Y3XzJGFMXCCyaH;zdIhwenmuYYTpc44hMHCDS2SpJIFv\CB2RVLQNUBxcG:|cHjvdplt[XSrb36gLJA1TUKSMTmgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NELNU4czPDZ7NU[zNi=>
SW982 MXzGeY5kfGmxbjDBd5NigQ>? NH3SdnMxNjBzLUCuOUDPxE1? MXeyOEBp MV3y[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= MUmyOFY6PTZ|Mh?=
SW872 M17KOmFxd3C2b4Ppd{BCe3OjeR?= M3m3b|AvODFvMD61JO69VQ>? MnzIOFghcA>? NGjlNmxqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NFPrbm4zPDZ7NU[zNi=>
SW982 NHXzVGZCeG:ydH;zbZMhSXO|YYm= Mn\oNE4xOS1yLkWg{txO MkDmOFghcA>? M3rBZolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= MnrYNlQ3QTV4M{K=
AGS HG NWe3WIl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwNkigxtEhOC5yM{Gg{txO MXGyOFU6PzR5OB?=
AGS LG NFvRNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz1TWM2OD1yLkC1JOKyKDBwMECxJO69VQ>? NX[5VIVHOjR3OUe0O|g>
HGC27 HG Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;1fIdKSzVyPUCuN|ghyrFiMD6wNlIh|ryP MWqyOFU6PzR5OB?=
HGC27 LG NGm2fnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr4fY5rUUN3ME2wMlAzKMLzIECuNFA1KM7:TR?= NEH1XlEzPDV7N{S3PC=>
MKN45 HG M1\wVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPhXnFKSzVyPUGuNFEhyrFiMD6wOVEh|ryP MoLwNlQ2QTd2N{i=
MKN45 LG NVXDcGF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PSTmlEPTB;MD64O{DDuSByLkCzNEDPxE1? MWGyOFU6PzR5OB?=
NUGC4 HG M1XNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLKTWM2OD1zND6wJOKyKDNwOUGzJO69VQ>? NE[0dGQzPDV7N{S3PC=>
NUGC4 LG MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonnTWM2OD1zND6wJOKyKDVwM{KxJO69VQ>? MorYNlQ2QTd2N{i=
A549 NF3tNIJHfW6ldHnvckBCe3OjeR?= NHfjcJUxNjJ3L{CuOU8yKM7:TR?= Mkf6NlQhcA>? NYXYc5hCcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|bHnnbJRtgQ>? M4HIR|I1OzVzNEK1
H460 NXTabnlsTnWwY4Tpc44hSXO|YYm= NVPISnFtOC5{NT:wMlUwOSEQvF2= M3;pXFI1KGh? M17ZdolvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2yrZ3j0cJk> M3jRbVI1OzVzNEK1
H661 NX:zbZZ7TnWwY4Tpc44hSXO|YYm= NEXRco4xNjJ3L{CuOU8yKM7:TR?= NEXDW3AzPCCq MlfrbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 NGLIPGEzPDN3MUSyOS=>
SAS M1PYcmZ2dmO2aX;uJGF{e2G7 NXrGRmFPOC5{NT:wMlUwOSEQvF2= MXKyOEBp MXPpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NEPubmYzPDN3MUSyOS=>
UT5 NEi5NZlHfW6ldHnvckBCe3OjeR?= MV6wMlI2NzBwNT:xJO69VQ>? NYjLdnVyOjRiaB?= MlHibY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 Mn60NlQ{PTF2MkW=
FaDu NGTXUodHfW6ldHnvckBCe3OjeR?= M4L2W|AvOjVxMD61M|Eh|ryP M3Lvb|I1KGh? MnPybY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 M2i3d|I1OzVzNEK1
RD NFzJUZNCeG:ydH;zbZMhSXO|YYm= M4DiclEwOS53L{Kg{txO NVTU[VBVPzJiaB?= MoDISG1UVw>? MmfIbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> MV:yN|Y5PDl{NR?=
TE671 NX3WVWhlSXCxcITvd4l{KEG|c3H5 MYCxM|EvPS9{IN88US=> M13MOlczKGh? Mm\sSG1UVw>? M2fRZolv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> NH;VV|AzOzZ6NEmyOS=>
RH30  MmfFRZBweHSxc3nzJGF{e2G7 MVexM|EvPS9{IN88US=> NHLzRow4OiCq MX7EUXNQ M3vw[Ylv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> M2X1NFI{Pjh2OUK1
RMS13 M3LWXWFxd3C2b4Ppd{BCe3OjeR?= MWSxM|EvPS9{IN88US=> Mn;MO|IhcA>? NX\RRo1zTE2VTx?= MYDpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 NGnJTJgzOzZ6NEmyOS=>
SUM149PT NXv6Zow4S2WubDDWbYFjcWyrdImgRZN{[Xl? NEm0b5UxNjNizszN MoLPO|IhcA>? M1yyWYVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? M2XxUFI{PjBzMEe0
MDA-MB-468 NFrNOVNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFPQOooxNjNizszN MnHnO|IhcA>? NGDocWlmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? M1Tqd|I{PjBzMEe0
MDA-MB-231 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{LMdlAvOyEQvF2= MVS3NkBp NFXHcHFmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? MnniNlM3ODFyN{S=
SY5Y NEK5PJBHfW6ldHnvckBCe3OjeR?= M3;yOFEvPS9{LkWvOUDPxE1? NETjTIYzPCCq Mn;MbY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= MYKyN|M4QDN2MR?=
SKNBE(2c) NV7qZ4ZiTnWwY4Tpc44hSXO|YYm= NX7nbZB2OS53L{KuOU82KM7:TR?= NYO1SIprOjRiaB?= NGKz[lZqdmS3Y3XzJGcyyqClZXzsMYN6[2ynIHHydoV{fCCjbnSgZZBweHSxc3nz M2PtNVI{Ozd6M{Sx
RD MUjBdI9xfG:|aYOgRZN{[Xl? M3XhPFMhyrWP Mm\3NVIhcA>? NWHnPZNXTE2VTx?= NHfTOWt{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnjaNlM{ODB6MEm=
TP5014 M{izSGFxd3C2b4Ppd{BCe3OjeR?= M2DKd|MhyrWP NVfTc5BZOTJiaB?= MoPuSG1UVw>? MY\z[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= NVzIR3dKOjN|MEC4NFk>
HT1080 MWnBdI9xfG:|aYOgRZN{[Xl? MkPaN{DDvU1? MnrSNVIhcA>? MVfEUXNQ MYnz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= MXyyN|MxODhyOR?=
A549 MkjRSpVv[3Srb36gRZN{[Xl? NFHlOWoxNTNwMzFOwG0> Mo[0O|IhcA>? NX3UR41icW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuW MoTPNlMzPTl3OUG=
HCC827 MnSxSpVv[3Srb36gRZN{[Xl? M1fCe|AuOy5|IN88US=> NXvYbZlQPzJiaB?= MoS0bY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV MXSyN|I2QTV7MR?=
H3122 MVPGeY5kfGmxbjDBd5NigQ>? M3ztOlAuOy5|IN88US=> MYO3NkBp NY\jNFNycW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuW NUK5bodVOjN{NUm1PVE>
TALL-1 NWCzNIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3OdJEy6oDLzszN MmjzO{Bl M1;UO4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NYHET441OjNyM{iyO|M>
HPB-ALL M3:5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\rcYhROeLCid88US=> MX23JIQ> MmrX[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NIjiWI0zOzB|OEK3Ny=>
DND41 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG2V4lIOeLCid88US=> NX\GO41nPyCm MmXz[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M{W4U|I{ODN6Mkez
SUP-T1 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[5OHdIOeLCid88US=> M3yx[|ch\A>? MVTk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NGPTPHozOzB|OEK3Ny=>
PEER MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PzSFHjiIoQvF2= NXroTZJtPyCm NFfFPYpl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? MYmyN|A{QDJ5Mx?=
ALL-SIL M1HK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TleVHjiIoQvF2= MofBO{Bl NGDDdZZl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NXrX[lBpOjNyM{iyO|M>
KE37 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjONgKBkc7:TR?= MmX3O{Bl MoH0[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MX2yN|A{QDJ5Mx?=
Karpas-45 NUPE[lcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33DSFHjiIoQvF2= M3fjTlch\A>? MVfk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MkH3NlMxOzh{N{O=
RPMI-8402 Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\pNgKBkc7:TR?= MlSyO{Bl MoHF[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M{DaR|I{ODN6Mkez
Jurkat Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rNgKBkc7:TR?= NEDubZg4KGR? M4e2WIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M1\xVFI{ODN6Mkez
MOLT-4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[5cVHjiIoQvF2= NFPReVA4KGR? M2TIbYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MXiyN|A{QDJ5Mx?=
PF-382 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTUXVZEOeLCid88US=> MojjO{Bl M1y5Z4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MmT6NlMxOzh{N{O=
CCRF-CEM MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTqbGVmOeLCid88US=> NVj1bIZEPyCm MWTk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M1rXS|I{ODN6Mkez
LOUCY NI\wNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\QNpIy6oDLzszN NHTROW44KGR? MlnY[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NHvvc5QzOzB|OEK3Ny=>
MOLT-16 MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKx5qCK|ryP MomzO{Bl M4XucoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MnHDNlMxOzh{N{O=
MM1S M1HDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HiUFAuOiEQvF2= M3PuZ|I1KGh? M2nhOmlEPTB;MD61JO69VQ>? NIXKWG8zOjh{OUKzOC=>
NCI-H929 M{Dm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPBZm0xNTJizszN NUDNPGVVOjRiaB?= M37STGlEPTB;MD6yOUDPxE1? MmPKNlI5Ojl{M{S=
KMS12-BM  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS0b3UxNTJizszN NXi5b|MzOjRiaB?= NWD6TmpmUUN3MP-8olIh|ryP NY[5Z4lwOjJ6MkmyN|Q>
MDA-MB-436 M{[wfWZ2dmO2aX;uJGF{e2G7 Mlm2NUDPxE1? NYjZcI1oOjRiaB?= NEXqNlJz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU M3HHNVIzPDh6NUmw
SUM149PT NH[0R3FHfW6ldHnvckBCe3OjeR?= MWSxJO69VQ>? MWGyOEBp NXfQXlRkemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MoLONlI1QDh3OUC=
SUM1315MO2 NHf0WWhHfW6ldHnvckBCe3OjeR?= M3TL[FEh|ryP M3jVVFI1KGh? MUPy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MWeyNlQ5QDV7MB?=
HCC1937 MWDGeY5kfGmxbjDBd5NigQ>? MlLhNUDPxE1? MVOyOEBp NXLD[4NMemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MlXRNlI1QDh3OUC=
HCC827 NIj3elFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fXc|AuOyEQvF2= NUHL[YY{PzJiaB?= MXjJR|UxRTBwMzFOwG0> M3e3bFIyOjJyNEe0
PC-9  MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoOzNE0{KM7:TR?= MYe3NkBp NEDlVItKSzVyPUCuPEDPxE1? NUDCXJZxOjF{MkC0O|Q>
LN229 M3fpUGZ2dmO2aX;uJGF{e2G7 MoftNUDPxE1? MYm0PEBp NHT2doZqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NEPITGgzOTB4Mkm5Ny=>
U87 Mk\vSpVv[3Srb36gRZN{[Xl? NHu3VGMyKM7:TR?= NXfNN4JVPDhiaB?= NYWzeHJOcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= Ml\UNlExPjJ7OUO=
U373 NX7sR2NbTnWwY4Tpc44hSXO|YYm= Mme3NUDPxE1? MV[0PEBp NVfz[mxqcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= NGnHNZAzOTB4Mkm5Ny=>
SF767 MVXGeY5kfGmxbjDBd5NigQ>? NXqwfnA1OSEQvF2= MUm0PEBp MojibY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? MVyyNVA3Ojl7Mx?=
Mel-Juso NX;jcpRGS2WubDDWbYFjcWyrdImgRZN{[Xl? MkfUNE4xOeLCk{Gw5qCK|ryP NETXWo44OiCq NYLKZ|BYcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M2DGbVIyODR6N{i1
518A2  NIq2UlBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIPFc5AxNjBz4pETNVDjiIoQvF2= MkfrO|IhcA>? M1XCcIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NWDoRYpkOjFyNEi3PFU>
Mel-Juso  MXXGeY5kfGmxbjDBd5NigQ>? MoS3NE4xODIkgKOx5qCK|ryP MoLVNlQhcA>? MW\zeZBxemW|c3XzJJBpd3OyaH;yfYxifGmxbjDv[kBxcG:|cHjheIllgWxiaX7vd4l1d2xiMz3rbY5ie2ViZH;3cpN1emWjbTD0ZZJo\XS| M3P2R|IyODR6N{i1
518A2 NEHZR|dHfW6ldHnvckBCe3OjeR?= MUKwMlAxOeLCk{JihKnPxE1? NWjDV5htOjRiaB?= NEnFTm5{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz NG\0boQzOTB2OEe4OS=>
PC3  NI\CV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fCTlI1cA>? NVLwN2R[T0l3MNMgQUAyODBibl2= MViyNFU2OTB4MR?=
U87MG NFjoVFFHfW6ldHnvckBCe3OjeR?= MWGwMlEuOSEQvF2= M1HrU|I16oDLaNMg MWLEUXNQ MmXVbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? NVHLcJIzOTl4M{O2PFM>
U138MG M3jGfGZ2dmO2aX;uJGF{e2G7 NXG3c21[OC5zLUGg{txO MY[yOQKBkWkEoB?= NW\qSpRQTE2VTx?= MlzObY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? NF3OdHoyQTZ|M{[4Ny=>
U118MG NGHL[3NHfW6ldHnvckBCe3OjeR?= NInrdYUxNjFvMTFOwG0> NFrxe40zPOLCiXlCpC=> M4\pVWROW09? MorRbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? NVfUfHhTOTl4M{O2PFM>
U87MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrtTWM2OD1yLkG0JO69VQ>? M3yyfFE6PTh2MkK3
IGROV-1 NIPrU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwME[g{txO NV;FWXZHOTl3OESyNlc>
DETROIT562 M4rIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm1V|VKSzVyPUCuNVMh|ryP NEW5blgyQTV6NEKyOy=>
PC3  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe4ZYVKSzVyPUCuNVAh|ryP Mm\ENVk2QDR{Mke=
SKOV-3 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHTS2hWUUN3ME2wMlEzKM7:TR?= NFXsZooyQTV6NEKyOy=>
HUVEC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HSO2lEPTB;MD6wPEDPxE1? NYS2R3hLOTl3OESyNlc>
UCH-1  NV3yUW9rTnWwY4Tpc44hSXO|YYm= MV2wMVUh|ryP M3PjUolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBCU1RiYX7kJI1VV1JiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3H2dlE6PTJ6NESx
UCH-1  MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jqZlAvODFvMUCg{txO NYnQbnB1PiCm NH;tSJJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHTvd4Uh\GWyZX7k[Y51dHl? NH\YSIIyQTV{OES0NS=>
UCH-1  M1X4XGFxd3C2b4Ppd{BCe3OjeR?= M3HCelAvOS1zMDFOwG0> M17JbFI1KGh? M2jBOWROW09? MmTYbY5lfWOnczDhdI9xfG:|aYO= MkPlNVk2Ojh2NEG=

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ